HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

N(6)- (4- amino- 3- iodobenzyl)adenosine- 5'- N- methyluronamide

binds to A3 adenosine receptors; structure in first source

Also Known As:

AB-MECA

Networked: 1 relevant articles (1 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Purines: 651
      - Purine Nucleosides: 360
        Adenosine: 12431
        N(6)-(4-amino-3-iodobenzyl)adenosine-5'-N-methyluronamide: 1
Nucleic Acids, Nucleotides, and Nucleosides: 1
- Nucleosides: 6847
  - Purine Nucleosides: 360
    - Adenosine: 12431
      - N(6)-(4-amino-3-iodobenzyl)adenosine-5'-N-methyluronamide: 1
  - Ribonucleosides: 49
    - Adenosine: 12431
      - N(6)-(4-amino-3-iodobenzyl)adenosine-5'-N-methyluronamide: 1

Experts

1.	Patel, Ashish: 1 article (01/2022)
2.	Patel, Leena: 1 article (01/2022)
3.	Patel, Mehul: 1 article (01/2022)
4.	Patel, Swayamprakash: 1 article (01/2022)
5.	Shah, Shaini: 1 article (01/2022)
6.	Shah, Umang: 1 article (01/2022)
7.	Solanki, Nilay: 1 article (01/2022)

Related Diseases

1.	Neoplasms (Cancer) 01/01/2022 - "Our aim was to study the efficacy of the adenosine receptor agonist, AB MECA, by in silico (molecular docking) and in vitro (human cancer cells in xenografted mice) studies. " 01/01/2022 - "AB MECA's higher binding energy (beng) with TNF-α mediated reduction of tumor growth in our lung cancer in vivo model suggested that it may be an effective therapy for lung cancer."
2.	Lung Neoplasms (Lung Cancer) 01/01/2022 - "Pharmacological Study of A3 Adenosine Receptor agonist (AB Meca) in Xenograft Lung Cancer Model in Mice through In Silico and In Vivo Approach: Targeting TNF-α." 01/01/2022 - "AB MECA's higher binding energy (beng) with TNF-α mediated reduction of tumor growth in our lung cancer in vivo model suggested that it may be an effective therapy for lung cancer."

Related Drugs and Biologics

1.	Purinergic P1 Receptors (Adenosine Receptor)

Related Therapies and Procedures

1.	Therapeutics